Literature DB >> 14994384

Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.

Ayako Kubota1, Kazuhisa Hasegawa, Toru Suguro, Yasuko Koshihara.   

Abstract

OBJECTIVE: To clarify the regulation of osteoprotegerin (OPG) expression in rheumatoid synovial fibroblasts by investigating the effect of tumor necrosis factor-alpha (TNF-alpha) and the mechanism of TNF-alpha-induced OPG expression.
METHODS: OPG expression was examined by Northern blot hybridization and reverse transcriptase-polymerase chain reaction in synovial fibroblasts from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) and subjects with no inflammatory condition. Amounts of OPG in conditioned medium were determined by ELISA. The effect of OPG on TNF-alpha-induced osteoclastogenesis was investigated in primary cultures of RA synovial cells.
RESULTS: OPG was highly expressed in RA synovial fibroblasts compared to OA and noninflammatory synovial fibroblasts. Different levels of OPG expression were found among patients with RA. TNF-alpha induced OPG expression in all synovial fibroblasts, even OA and noninflammatory fibroblasts, and expression occurred to a remarkable degree in RA fibroblasts. The OPG expression was upregulated by TNF-alpha in a time- and dose-dependent manner. TNF-alpha-induced OPG expression was inhibited by hymenialdisine, a nuclear factor-kappaB inhibitor, in a dose-dependent manner, and expression was inhibited by soluble TNF receptor/Fc fusion protein I (TNFs-RI/Fc), not by TNFs-RII/Fc. In contrast, TNF-alpha-induced osteoclastogenesis in primary cultures of RA synovial cells was inhibited by the addition of OPG.
CONCLUSION: These results suggest that OPG is highly expressed and is upregulated by TNF-alpha in rheumatoid synovial fibroblasts. TNF-alpha-induced OPG expression is mediated predominantly through TNF-RI. Although TNF-alpha is known to stimulate bone destruction, TNF-alpha-induced upregulation of OPG may contribute to self-protection from the bone destruction in RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14994384

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Application of molecular, microbiological, and immunological tests for the diagnosis of bone and joint tuberculosis.

Authors:  Yinghua Tang; Lianli Yin; Shifu Tang; Hongyu Zhang; Jihui Lan
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

2.  Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis.

Authors:  Kazuhiro Maeda; Yasuhiro Kobayashi; Nobuyuki Udagawa; Shunsuke Uehara; Akihiro Ishihara; Toshihide Mizoguchi; Yuichiro Kikuchi; Ichiro Takada; Shigeaki Kato; Shuichi Kani; Michiru Nishita; Keishi Marumo; T John Martin; Yasuhiro Minami; Naoyuki Takahashi
Journal:  Nat Med       Date:  2012-02-19       Impact factor: 53.440

Review 3.  Circulating osteoprotegerin levels are elevated in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Peng Wang; Si Li; Li-Na Liu; Tian-Tian Lv; Xiao-Mei Li; Xiang-Pei Li; Hai-Feng Pan
Journal:  Clin Rheumatol       Date:  2017-07-11       Impact factor: 2.980

4.  Regulatory effects of bone morphogenetic protein-4 on tumour necrosis factor-α-suppressed Runx2 and osteoprotegerin expression in cementoblasts.

Authors:  Yunlong Wang; Hong He; Zhengguo Cao; Yi Fang; Mingyuan Du; Zhijian Liu
Journal:  Cell Prolif       Date:  2017-02-28       Impact factor: 6.831

5.  Osteoclast-Associated Receptor (OSCAR) Distribution in the Synovial Tissues of Patients with Active RA and TNF-α and RANKL Regulation of Expression by Osteoclasts In Vitro.

Authors:  Anak A S S K Dharmapatni; Kent Algate; Roxanne Coleman; Michelle Lorimer; Melissa D Cantley; Malcolm D Smith; Mihir D Wechalekar; Tania N Crotti
Journal:  Inflammation       Date:  2017-10       Impact factor: 4.092

6.  Combination therapy with dexamethasone and osteoprotegerin protects against arthritis-induced bone alterations in antigen-induced arthritis of the rat.

Authors:  P Oelzner; S Fleissner-Richter; R Bräuer; G Hein; G Wolf; T Neumann
Journal:  Inflamm Res       Date:  2010-03-20       Impact factor: 4.575

7.  Synovial fibroblasts infected with Salmonella enterica serovar Typhimurium mediate osteoclast differentiation and activation.

Authors:  Xiang Zhang; Jane E Aubin; Tae-Hwan Kim; Ursula Payne; Basil Chiu; Robert D Inman
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

8.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

9.  Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Authors:  Janine L Oliver; Matthew P Alexander; Allison G Norrod; Irene M Mullins; David W Mullins
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-11       Impact factor: 4.693

10.  Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6.

Authors:  Tiffany J Dickerson; Erika Suzuki; Catherine Stanecki; Hyun-Seock Shin; Hong Qui; Iannis E Adamopoulos
Journal:  J Autoimmun       Date:  2012-08-03       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.